A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 26, 2015

Conditions

Ischemic CardiomyopathyNon-ischemic CardiomyopathyHeart FailureCardiomyopathies

Interventions

GENETIC

MYDICAR Phase 1

Single dose of MYDICAR

GENETIC

MYDICAR Phase 2

Single dose of MYDICAR

GENETIC

Placebo Phase 2 only

Single dose of placebo

Trial Locations (4)

La Jolla

San Diego

Kansas City

New York